Archives of Endocrinology and Metabolism · مجلد 70 (5) · 1-21
Objective: To quantify hepatic steatosis and visceral adiposity in active Cushing’s syndrome (CS) using magnetic resonance imaging (MRI), evaluate associations between hypercortisolism and MRI-derived fat metrics, and characterize the relationship between hepatic and visceral fat compartments. Subjects and methods: This retrospective cross-sectional study assessed 36 patients with biochemically confirmed active CS. Hepatic proton density, fat fraction, and visceral adipose tissue area were quantified using chemical-shift encoded MRI with semi-automated segmentation. Biochemical assessments included serum cortisol, adrenocorticotropic hormone, liver enzymes, and lipid profiles. Results: MRI-defined hepatic steatosis (fat fraction ≥6.25%) was identified in 69.4% (25/36) of patients. Those with steatosis exhibited higher serum cortisol levels (832.9 ± 347.8 vs. 581.2 ± 331.9 nmol/L, p = 0.049) and greater visceral adiposity (35.0 ± 8.0 vs. 23.9 ± 6.7 cm2, p < 0.001). Serum cortisol positively correlated with visceral fat area (r = 0.512, p = 0.001) and inversely correlated with liver signal intensity index (r = -0.424, p = 0.01). Visceral adiposity demonstrated a strong positive correlation with hepatic steatosis grade (r = 0.601, p < 0.001). Conclusion: Hepatic steatosis was highly prevalent in active CS and closely linked to hypercortisolism and visceral adiposity. These findings support a mechanistic coupling between central and ectopic fat accumulation. Integrated MRI-based fat quantification provides a non-invasive, radiation-free approach for refined cardiometabolic risk stratification in this high-risk population.
BACKGROUND: Diabetic peripheral neuropathy (DPN) is a common and costly complication that occurs in both Type 1 and Type 2 diabetes mellitus. The prevalence of neuropathy is estimated to be around 8% in newly diagnosed patients and exceeds 50% in those with long-standing disease. The aim of this study was to determine the prevalence of DPN among individuals with Type 2 diabetes mellitus in Sudan and to identify the factors associated with DPN. METHODOLOGY: This cross-sectional study was conducted in the outpatient setting of an endocrinology clinic at a tertiary care centre (Diabetes Specialized Centres) in Khartoum State between January 2020 and January 2021. RESULTS: Out of the 236 patients included in the study, the mean age was 55.7 ± 11.5 years, and 54.7% were female. The prevalence of DPN was found to be 43%. Logistic regression analysis revealed that the following factors were significantly associated with DPN: body mass index (BMI) (P = 0.022, OR = 3.733), male gender (P = 0.003, OR = 7.165), educational level (P = 0.034, OR = 20.577), duration of diabetes (P = 0.014, OR = 13.121), age (P = 0.001, OR = 2.735), HbA1c level (P = 0.002, OR = 1.782), alcohol consumption (P = 0.000, OR = 212.158), smoking status (P = 0.005, OR = 0.063), and the presence of hypertension (P = 0.001, OR = 11.493). CONCLUSION: There a relatively high prevalence of DPN in the diabetic population of Sudan, and significantly associated with the duration of diabetes, BMI, age, HbA1c levels, male gender, alcohol consumption, smoking status, and hypertension. Regular screening and patient education are needed to reduce DPN in Sudanese patients with diabetes. CLINICAL TRIAL NUMBER: NA.
Frontiers in Endocrinology · مجلد 13 · 862394-862394
The current study aims to assess the protective effects of dapagliflozin (Dapa; a sodium-glucose cotransporter-2 inhibitor) and/or liraglutide (Lira; a glucagon-like peptide 1 agonist) in an experimental model of diabetic cardiomyopathy (DCM). A single dose of streptozotocin (STZ) was administrated to male Sprague-Dawley rats by intraperitoneal injection at a dose of 50 mg/kg to induce diabetes mellitus (DM). Dapa (1 mg/kg, orally), Lira (0.4 mg/kg, s.c.), and Dapa-Lira combination were administrated for 8 weeks once-daily. Blood samples were evaluated for glucose level and biochemical markers of cardiac functions. Cardiac tissue was dissected and assessed for redox homeostasis (malondialdehyde (MDA), glutathione (GSH), and catalase (CAT)), pro-inflammatory mediators (NF-κB and tumor necrosis factor-α (TNF-α)), and apoptotic effectors (caspase-3). Moreover, the effect of treatments on the cardiac cellular structure was studied. Dapa and/or Lira administration resulted in significant improvement of biochemical indices of cardiac function. Additionally, all treatment groups demonstrated restoration of oxidant/antioxidant balance. Moreover, inflammation and apoptosis key elements were markedly downregulated in cardiac tissue. Also, histological studies demonstrated attenuation of diabetes-induced cardiac tissue injury. Interestingly, Dapa-Lira combination treatment produced a more favorable protective effect as compared to a single treatment. These data demonstrated that Dapa, Lira, and their combination therapy could be useful in protection against DM-accompanied cardiac tissue injury, shedding the light on their possible utilization as adjuvant therapy for the management of DM patients.